ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia - Episode 3
Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.
Related Content: